Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

20-09-2016 | Endocrine cancers | Book chapter | Article

99. Chemotherapy for Anaplastic Thyroid Cancer

Authors: David A. Liebner, MD, Sigurdis Haraldsdottir, MD, Manisha H. Shah, MD

Publisher: Springer New York

Login to get access

Abstract

Anaplastic thyroid cancers (ATC) account for roughly 2.2 % of all thyroid cancers in the USA (Hossain et al. J Clin Oncol 28(15s):abstr 5588, 2010) and are believed to arise from differentiated thyroid cancers (DTC) via the accumulation of genetic abnormalities that result in dedifferentiation and an aggressive phenotype (Wiseman et al. J Clin Oncol 24(18s):abstr 5556, 2006). Unfortunately, ATC is usually advanced at the time of diagnosis, with approximately 76–79 % of all patients having disease extending beyond the thyroid/neck at the time of presentation (Hossain et al. J Clin Oncol 28(15s):abstr 5588, 2010; Chen et al. Am J Clin Oncol 31(5):460–4, 2008). In the vast majority of patients, surgery alone has been associated with poor outcomes, leading to investigation into additional therapeutic options.
Literature
1.
Hossain A, et al. Epidemiology, treatment outcome, and survival of anaplastic thyroid cancer (ATC) in the United States: a period prevalence SEER database study 1973–2006. J Clin Oncol. 2010;28(15s):abstr 5588.
2.
Wiseman S, et al. Derangement of p53 and MDM2 is involved in transformation of differentiated into anaplastic thyroid cancer. J Clin Oncol. 2006;24(18s):abstr 5556.
3.
Chen J, et al. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983–2002. Am J Clin Oncol. 2008;31(5):460–4.CrossRefPubMed
4.
Schoumacher P, et al. Anaplastic carcinoma of the thyroid gland. Eur J Cancer. 1977;13(4–5):381–3.CrossRefPubMed
5.
Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg. 1980;23(1):25–7.PubMed
6.
Gottlieb JA, Hill Jr CS. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974;290(4):193–7.CrossRefPubMed
7.
Shimaoka K, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56(9):2155–60.CrossRefPubMed
8.
De Besi P, et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest. 1991;14(6):475–80.CrossRefPubMed
9.
Tamura K, et al. Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte granulocyte colony-stimulating factor support. Chemotherapy Committee, The Japanese Society of Thyroid Surgery. Jpn J Clin Oncol. 1995;25(5):203–7.
10.
Gottlieb JA, et al. Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer. 1972;30(3):848–53.CrossRefPubMed
11.
Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10(7):587–94.CrossRefPubMed
12.
Higashiyama T, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20(1):7–14.CrossRefPubMed
13.
Kawada K, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol. 2010;40(6):596–9.CrossRefPubMed
14.
Stevenson JP, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003;21(23):4428–38.CrossRefPubMed
15.
Mooney CJ, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19(3):233–40.CrossRefPubMedPubMedCentral
16.
Sosa JA, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. J Clin Oncol. 2011;29(15s):abstr 5502.
17.
Gramza A, et al. Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: phase I results. J Clin Oncol. 2013;31(suppl):abstr 6074.
18.
Ha HT, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20(9):975–80.CrossRefPubMed
19.
Schiff BA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004;10(24):8594–602.CrossRefPubMed
20.
Hogan T, et al. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract. 2009;15(2):111–7.CrossRefPubMed
21.
Pennell NA, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18(3):317–23.CrossRefPubMed
22.
Gupta-Abramson V, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–9.CrossRefPubMedPubMedCentral
23.
Kloos RT, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675–84.CrossRefPubMedPubMedCentral
24.
Cohen EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–13.CrossRefPubMedPubMedCentral
25.
Lorch J, et al. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). J Clin Oncol. 2013;31(suppl):abstr 6023.
26.
Lee Y, et al. Multimodal therapeutic approach in anaplastic thyroid cancer. J Clin Oncol. 2006;24(18s):abstr 15533.
27.
Orita Y, et al. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery. 2011;150(6):1212–9.CrossRefPubMed
28.
Tennvall J, et al. Undifferentiated giant and spindle cell carcinoma of the thyroid. Report on two combined treatment modalities. Acta Radiol Oncol Radiat Phys Biol. 1979;18(5):408–16.CrossRefPubMed
29.
Tallroth E, et al. Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer. 1987;60(7):1428–31.CrossRefPubMed
30.
Tennvall J, et al. Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol. 1990;29(8):1025–8.CrossRefPubMed
31.
Tennvall J, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994;74(4):1348–54.CrossRefPubMed
32.
Nilsson O, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg. 1998;22(7):725–30.CrossRefPubMed
33.
Tennvall J, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86(12):1848–53.CrossRefPubMedPubMedCentral
34.
Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg. 2004;93(4):272–7.PubMed
35.
Andersson T, et al. Combined therapy for undifferentiated giant and spindle cell carcinoma of the thyroid. Acta Otolaryngol. 1977;83(3–4):372–7.CrossRefPubMed
36.
Werner B, et al. Multimodal therapy in anaplastic giant cell thyroid carcinoma. World J Surg. 1984;8(1):64–70.CrossRefPubMed
37.
Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987;60(10):2372–5.CrossRefPubMed
38.
Schlumberger M, et al. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer. 1991;67(3):564–6.CrossRefPubMed
39.
Tanaka K, Sugitani I, Fujimoto Y. A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. Jpn J Clin Oncol. 2011;41(9):1074–8.CrossRefPubMed
40.
Foote RL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21(1):25–30.CrossRefPubMed
41.
Sugawara I, et al. Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid. Cancer Lett. 1994;82(2):185–8.CrossRefPubMed
42.
Lavra L, et al. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol. 2009;218(1):66–75.CrossRefPubMed